UNSPSC 51434909: Amlodipine/olmesartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434909 Amlodipine/olmesartan is a Commodity code covering specific pharmaceutical products purchased by state and local government health and safety agencies. State and local buyers use this code to procure branded and generic antihypertensive medications for emergency medical services, public health programs, and state pharmacy benefit systems. Recent solicitations show that municipalities and state health agencies are acquiring these medications through competitive bid processes, cooperative purchasing agreements, and direct-to-manufacturer procurement pilots. The City of Tampa's Fire Rescue system, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of issuing bodies—municipal fire departments, state health agencies, and regional cooperative purchasing vehicles—that source these products. Procurement mechanics range from sealed competitive bids for specific unit quantities to statewide cooperative RFPs establishing framework agreements with multiple manufacturers and wholesalers, reflecting the breadth of demand across emergency medical, hospital, and state pharmacy benefit contexts.

Recent activity concentrates in Texas, Florida, and Minnesota. The City of Tampa issued a sealed bid (26P00188) due April 8, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem totaling an estimated contract value of $40,000, with a one-year initial term and renewal options. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013) on April 3, 2026, to assess vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling state-level interest in alternative procurement pathways. The Minnesota Department of Administration, administering MMCAP, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products, with awards effective July 1, 2026, requiring compliance with cGMP, the Drug Supply Chain Security Act, and relationships with authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson. Activity reflects ongoing demand for emergency medical supply replenishment and state-level cost-management initiatives targeting pharmacy benefit programs.